Research ExplorerPublicationsMedulloblastoma

Medulloblastoma

Standard

Medulloblastoma. / Northcott, Paul A; Robinson, Giles W; Kratz, Christian P; Mabbott, Donald J; Pomeroy, Scott L; Clifford, Steven C; Rutkowski, Stefan; Ellison, David W; Malkin, David; Taylor, Michael D; Gajjar, Amar; Pfister, Stefan M.

In: NAT REV DIS PRIMERS, Vol. 5, No. 1, 14.02.2019, p. 11.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Northcott, PA, Robinson, GW, Kratz, CP, Mabbott, DJ, Pomeroy, SL, Clifford, SC, Rutkowski, S, Ellison, DW, Malkin, D, Taylor, MD, Gajjar, A & Pfister, SM 2019, 'Medulloblastoma', NAT REV DIS PRIMERS, vol. 5, no. 1, pp. 11. https://doi.org/10.1038/s41572-019-0063-6

APA

Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., Gajjar, A., & Pfister, S. M. (2019). Medulloblastoma. NAT REV DIS PRIMERS, 5(1), 11. https://doi.org/10.1038/s41572-019-0063-6

Vancouver

Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC et al. Medulloblastoma. NAT REV DIS PRIMERS. 2019 Feb 14;5(1):11. https://doi.org/10.1038/s41572-019-0063-6

Bibtex

@article{49e05949b5074bfea19f951071e5d804,
title = "Medulloblastoma",
abstract = "Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog (SHH), Group 3 and Group 4), each of which is associated with different genetic alterations, age at onset and prognosis. These subgroups have broadly been incorporated into the WHO classification of central nervous system tumours but still need to be accounted for to appropriately tailor disease risk to therapy intensity and to target therapy to disease biology. In this Primer, the epidemiology (including MB predisposition), molecular pathogenesis and integrative diagnosis taking histomorphology, molecular genetics and imaging into account are reviewed. In addition, management strategies, which encompass surgical resection of the tumour, cranio-spinal irradiation and chemotherapy, are discussed, together with the possibility of focusing more on disease biology and robust molecularly driven patient stratification in future clinical trials.",
keywords = "Chemotherapy, Adjuvant/methods, Humans, Magnetic Resonance Imaging/methods, Mass Screening/methods, Medulloblastoma/diagnosis, Prognosis, Quality of Life/psychology, Risk Factors",
author = "Northcott, {Paul A} and Robinson, {Giles W} and Kratz, {Christian P} and Mabbott, {Donald J} and Pomeroy, {Scott L} and Clifford, {Steven C} and Stefan Rutkowski and Ellison, {David W} and David Malkin and Taylor, {Michael D} and Amar Gajjar and Pfister, {Stefan M}",
year = "2019",
month = feb,
day = "14",
doi = "10.1038/s41572-019-0063-6",
language = "English",
volume = "5",
pages = "11",
journal = "NAT REV DIS PRIMERS",
issn = "2056-676X",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Medulloblastoma

AU - Northcott, Paul A

AU - Robinson, Giles W

AU - Kratz, Christian P

AU - Mabbott, Donald J

AU - Pomeroy, Scott L

AU - Clifford, Steven C

AU - Rutkowski, Stefan

AU - Ellison, David W

AU - Malkin, David

AU - Taylor, Michael D

AU - Gajjar, Amar

AU - Pfister, Stefan M

PY - 2019/2/14

Y1 - 2019/2/14

N2 - Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog (SHH), Group 3 and Group 4), each of which is associated with different genetic alterations, age at onset and prognosis. These subgroups have broadly been incorporated into the WHO classification of central nervous system tumours but still need to be accounted for to appropriately tailor disease risk to therapy intensity and to target therapy to disease biology. In this Primer, the epidemiology (including MB predisposition), molecular pathogenesis and integrative diagnosis taking histomorphology, molecular genetics and imaging into account are reviewed. In addition, management strategies, which encompass surgical resection of the tumour, cranio-spinal irradiation and chemotherapy, are discussed, together with the possibility of focusing more on disease biology and robust molecularly driven patient stratification in future clinical trials.

AB - Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog (SHH), Group 3 and Group 4), each of which is associated with different genetic alterations, age at onset and prognosis. These subgroups have broadly been incorporated into the WHO classification of central nervous system tumours but still need to be accounted for to appropriately tailor disease risk to therapy intensity and to target therapy to disease biology. In this Primer, the epidemiology (including MB predisposition), molecular pathogenesis and integrative diagnosis taking histomorphology, molecular genetics and imaging into account are reviewed. In addition, management strategies, which encompass surgical resection of the tumour, cranio-spinal irradiation and chemotherapy, are discussed, together with the possibility of focusing more on disease biology and robust molecularly driven patient stratification in future clinical trials.

KW - Chemotherapy, Adjuvant/methods

KW - Humans

KW - Magnetic Resonance Imaging/methods

KW - Mass Screening/methods

KW - Medulloblastoma/diagnosis

KW - Prognosis

KW - Quality of Life/psychology

KW - Risk Factors

U2 - 10.1038/s41572-019-0063-6

DO - 10.1038/s41572-019-0063-6

M3 - SCORING: Review article

C2 - 30765705

VL - 5

SP - 11

JO - NAT REV DIS PRIMERS

JF - NAT REV DIS PRIMERS

SN - 2056-676X

IS - 1

ER -